In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients

Abstract

In this report we compare the activity of two new antifungal agents, voriconazole (UK-109,496) and LY303366 with the activities of other antifungals including fluconazole, itraconazole, 5-fluorocytosine (5FC) and amphotericin B against 219 oral Candida spp. isolates from HIV-infected patients. We used the broth microdilution method following the guidelines of the NCCLS. The in-vitro activity of voriconazole (UK-109,496) (MIC(90) 0.12 mg/L) and LY303366 (CMI(90) 0.25 mg/L) against clinical isolates of Candida spp. was excellent and comparable with that of amphotericin B (MIC(90) 0.5 mg/L), and better than those of fluconazole (MIC(90) > or = 64 mg/L), itraconazole (MIC(90) 4 mg/L) and 5FC (MIC(90) 1 mg/L).

Actividad in vitro de voriconazol y otros tres antifúngicos frente a dermatofitos

“…Los agentes antifúngicos más utilizados en el tratamiento de estas infecciones son la terbinafina y el itraconazol 7,8 . En los últimos años han aparecido nuevos agentes antifúngicos con buena actividad frente a gran variedad de hongos, uno de ellos es el voriconazol, que se caracteriza por ser un triazol con estructura similar al fluconazol y excelente actividad frente a levaduras, hongos dimórficos y hongos filamentosos oportunistas [9][10][11][12][13] . El objetivo de este estudio fue comparar la actividad in vitro de este nuevo antifúngico, voriconazol, frente a otros tres antifúngicos de actividad ya conocida, fluconazol, itraconazol y terbinafina utilizando el método de microdilución en caldo propuesto por el National Committee for Clinical Laboratory Standards (NCCLS) (M38-P) con algunas modificaciones 14 .…”

In vitroactivity of voriconazole against Mexican oral yeast isolates

“…Candidiasis is the most prevalent oral complication in HIV‐infected and AIDS (HIV+/AIDS) patients. Candida albicans represents the most common causative agent; however, other species of Candida have begun to emerge 1–3 . The introduction of highly active antiretroviral therapy (HAART) in clinical practice has reduced the prevalence of oral candidiasis but this antiviral therapy is far from being universal and many Mexican HIV+/AIDS patients do not normally receive it.…”

Solution Structure of a Designed Amphipathic Antimicrobial Synthetic Peptide, PGAa

“…It has been isolated from the toothbrushes, for people carry the yeast in their mouths, and even survives in hand cream, cosmetics, and on clothing. Although oropharyngeal and oesophageal candidosis are common fungal infections in HIV-infected patients, fluconazole has been shown to be effective in the treatment of these mycoses; however, its widespread use has been accompanied by the emergence of resistant isolates, mainly in HIV-infected patients (10).…”